Early Intervention in Cerebral Palsy: Perception-Action vs Neurodevelopmental Therapy

Efficacy of the Perception-Action Approach Versus Neurodevelopmental Therapy in Early Intervention for Children With Cerebral Palsy: A Randomized Controlled Trial

The goal of this clinical trial is to compare two different physiotherapy approaches used in early intervention for children with cerebral palsy. These approaches are the Perception-Action Approach and Neurodevelopmental Therapy (Bobath). The study aims to understand which approach is more effective in supporting neurodevelopmental outcomes in early childhood in Cerebral Palsy.

The main questions this study aims to answer are:

How does the Perception-Action Approach affect motor function in young children with cerebral palsy? How does Neurodevelopmental Therapy (Bobath) affect motor function in young children with cerebral palsy? Are there differences in outcomes between these two approaches?

Researchers will compare these two approaches to see which one better supports motor development.

Participants will:

Be children aged 0 to 36 months with cerebral palsy or at high risk Be assigned to one of the two therapy groups Receive one therapy session per week for 12 weeks Be assessed before and after the intervention using standardized tests

The results of this study may help therapists and families choose the most effective early intervention approach for children with cerebral palsy.

Inclusion Criteria:

• Diagnosis of Cerebral Palsy
• Being at high risk for Cerebral Palsy (based on MRI or cranial ultrasound findings and neurological examination)
• Age between 0-36 months (using corrected age for preterm infants)
• Parental agreement to participate in the study and attend all assessment and therapy sessions; signed informed consent form from the parent(s) or legal guardian(s)

Exclusion Criteria:

• Presence of severe visual or hearing impairment that would prevent full participation in therapy sessions
• Uncontrolled seizures
• Receipt of botulinum toxin injection or orthopedic surgery within the last 6 months
• Diagnosis of an additional neurometabolic, genetic, or other neurological disorder